Phoenix Bio

研究発表

研究発表

RXR agonist S169 inhibits HBV/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking

    Gad, S. A. Abo Elwafa, D. A. Hussein, S. A. Fukano, K. Kato, T. Shoji, I. Chayama, K. Muramatsu, M. Isogawa, M. Wakita, T. Merk, D. Aly, H. H.
    Antiviral Res. 2025 Aug;240:106214. doi: 10.1016/j.antiviral.2025.106214.

    A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide

      Rsi Suwardana, G. N. Abe, T. Deng, L. Matsui, C. Okitsu, T. Yamada, T. Hatano, M. Wiriyasermkul, P. Nagamori, S. Gad, S. A. Aly, H. H. Nishitsuji, H. Shimotohno, K. Shoji, I.
      Antiviral Res. 2025 Aug 30;243:106267. doi: 10.1016/j.antiviral.2025.106267.

      Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

        Takamatsu, S. Morita, C. Sakon, D. Nakamura, K. Hishii, H. Kondo, J. Ueda, K. Miyoshi, E.
        Viruses. 2025 Sep 15;17(9):1242. doi: 10.3390/v17091242.

        Modeling of hepatitis B virus infection spread in primary human hepatocytes

          Shi, Z. Tsuge, M. Collier, N. Takeuchi, Y. Uchida, T. Rutter, C. M. Teraoka, Y. Uprichard, S. L. Ishida, Y. Tateno, C. Ozik, J. Dahari, H. Chayama, K.
          J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927-25.

          Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model

            Visser, B. J. Biswas, S. Eltahan, R. Fares-Gusmao, R. Yegneswaran, S. Mufti, N. Villa, C. H. McGivern, D. R.
            Transfusion. 2025 Jul 24. doi: 10.1111/trf.18357.

            miRNA-29b-1-5p mediates an antiviral activity by targeting the HBV entry receptor in human hepatocytes

              Gailhouste, L. Furutani, Y. Qin, X. Y. Higuchi, S. Toguchi, M. Yanaka, K. Watashi, K. Wakita, T. Kojima, S.
              Sci Rep. 2025 Jul 3;15(1):23725. doi: 10.1038/s41598-025-09655-y.

              Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

                Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
                JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

                Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

                  Tanaka, Yasuhito
                  Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

                  Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening

                    Nishitsuji, H. Naito, Y. Murakami, Y. Sugiyama, M. Mizokami, M. Shoji, I. Murata, T. Shimotohno, K.
                    Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.

                    Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems

                      Nosaka, T. Naito, T. Akazawa, Y. Takahashi, K. Matsuda, H. Ohtani, M. Nishizawa, T. Okamoto, H. Nakamoto, Y.
                      PLoS One. 2025 Mar 6;20(3):e0314581. doi: 10.1371/journal.pone.0314581.

                      Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

                        Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
                        FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

                        Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

                          Zhang, M. Mouzannar, K. Zhang, Z. Teraoka, Y. Piotrowski, J. Ishida, Y. Tateno-Mukaidani, C. Saito, T.Abe-Chayama, H. Chayama, K.Liang, T. J.
                          PLoS Pathog. 2025 Jan 9;21(1):e1012803. doi: 10.1371/journal.ppat.1012803.

                          Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

                            Bao, H. Murakami, S. Tsuge, M. Uchida, T. Uchikawa, S. Fujino, H. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Hayes, C. N. Oka, S.
                            Viruses. 2024 Nov 6;16(11):1743. doi: 10.3390/v16111743.

                            Modelling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes

                              Louis Shekhtman, Yuji Ishida, Masataka Tsuge, Vladimir Reinharz, Mikaru Yamao, Masaki Takahashi, Chise Tateno, Susan L. Uprichard, Harel Dahari, Kazuaki Chayama
                              JHEP Reports https://doi.org/10.1016/j.jhepr.2024.101311.

                              Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?

                                El Ekiaby, M. Tanaka, J. van Drimmelen, H. Allain, J. P. Lelie, N.
                                J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.

                                Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

                                  Duehren, S. Uchida, T. Tsuge, M. Hiraga, N. Uprichard, S. L. Etzion, O. Glenn, J. Koh, C. Heller, T. Cotler, S. J. Oka, S. Chayama, K. Dahari, H.
                                  Virus Res. 2024 Aug 26;349:199451. doi: 10.1016/j.virusres.2024.199451.

                                  Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice

                                    Okada, H. Sakamoto, T. Nio, K. Li, Y. Kuroki, K. Sugimoto, S. Shimakami, T. Doi, N. Honda, M. Seiki, M. Kaneko, S. Yamashita, T.
                                    Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101289. doi: 10.1016/j.omtm.2024.101289.

                                    Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein

                                      Kornyeyev, D. Song, Z. Eng, S. Soulette, C. Ramirez, R. Tang, J. Yue, Q. Subramanian, R. Zaboli, S. Moon, C. Tam, J. Brodbeck, J. Aggarwal, A. Diehl, L. Fletcher, S. P. Hyrina, A. Holdorf, M. M. Burdette, D.
                                      Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0042024. doi: 10.1128/aac.00420-24.

                                      Antiviral effect of peptoids on hepatitis B virus infection in cell culture

                                        Murayama, A. Igarashi, H. Yamada, N. Aly, H. H. Molchanova, N. Lin, J. S. Nishitsuji, H. Shimotohno, K. Muramatsu, M. Barron, A. E. Kato, T.
                                        Antiviral Res. 2024 Mar;223:105821. doi: 10.1016/j.antiviral.2024.105821.

                                        An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity

                                          Tang, L. Remiszewski, S. Snedeker, A. Chiang, L. W. Shenk, T.
                                          Antiviral Res. 2024 Jun;226:105888. doi: 10.1016/j.antiviral.2024.105888.